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Abstract
Ovarian cancer is the main cause of death among all reproductive cancers in females. In 2018, ovarian cancer was
the seventh most common cancer of women entire the world. A wide variety of molecular and genetic alterations
as well as different response to therapies in the different types of ovarian cancer lead to problems in design a
common therapeutic strategy. Besides, ovarian cancer cells have tendency to acquire resistance to common cancer
treatments through multiple mechanisms. Various factors, including cytokines, growth factors, proteases, adhesion
molecules, coagulation factors, hormones and apoptotic agents have been examined to find effective cancer
treatment. Phytochemicals have been indicated to have great potential anti-cancer properties against various types
of cancers. Quercetin is one of the phytochemicals that exists extensively in daily foods. Wide evidences revealed
that quercetin is able to inhibit various types of cancers including breast, lung, nasopharyngeal, kidney, colorectal,
prostate, pancreatic, and ovarian cancer. Several in vitro and in vivo studied conducted to evaluate cytotoxic effects
of quercetin on ovarian cancer. Since quercetin does not harm healthy cells and it is cytotoxic to cancer cells via
various mechanisms, researchers suggest that it could be an ideal agent for ovarian cancer treatment or an
adjuvant agent in combination with other anti-cancer drugs. Thus, in this review, we focused on chemo-preventive
and curative attitude of quercetin for ovarian cancer and summarize some of the most recent findings which
regard the possible molecular mechanisms by which this natural compound inhibits this cancer.
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Introduction
Ovarian cancer is the most fetal of all reproductive can-
cers, the eleventh most common type, and the fifth main
cause of cancer-associated death in women. In 2018,
ovarian cancer was the seventh most frequent cancer of
females globally, with about 240.000 new subjects [1].
Ovarian cancer is commonly not diagnosed until ad-
vanced stages because of its silent and obscure symp-
toms which make it hard to cure appropriately [2]. In
spite of widespread awareness of this cancer in these
years, its survival rate has not significantly changed due
to difficulties existing in its early diagnosis [3]. Some
common symptoms of ovarian cancer are including ab-
dominal pain, abdominal bloating, urinary frequency and
changes in bowel habits [2, 4]. It is essential for health
care supporters to consider these vague and non-specific
symptoms especially in high-risk cases. Several risk
factors, including family history or genetic predispos-
ition, ovulation, endometriosis, dietary factors, and race
has been known for this disorder [5]. Ovarian cancer di-
vided into 3 types: epithelial (most frequent), germ cell,
and sex-cord-srtomal. Epithelial ovarian cancer has four
histological subtypes: serous, endometrioid, mucinous
and clear cell [2]. The various molecular and genetic al-
terations of these types of ovarian cancer as well as their
different responses to therapies lead to a challenge in de-
sign a common treatment strategy [6]. In ovarian cancer,
the tumor microenvironment is consist of immune cells,
fibroblasts, extracellular matrix (ECM), some enzymes
such as matrix metalloproteinase (MMPs), and growth
factors such as vascular endothelial growth factor
(VEGF), transforming growth factor- β (TGF-β), and
platelet-derived growth factor (PDGF). These compo-
nents promote tumor cell proliferation, migration and
invasion [7].
Ovarian cancer cells are willing to establish resistance
to common cancer therapies. Cancer cells are able to
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acquire drug-resistance via multiple mechanisms [8]. A
large number of factors, including inflammatory cyto-
kines, growth factors, proteases, adhesion molecules, co-
agulation factors, hormones, and apoptotic agents have
been evaluated in order to find effective cancer treat-
ment. Wide experimental studies have demonstrated
that phytochemicals such as polyphenols, flavones and
flavonoids exert great potential anti-cancer properties
against various types of cancers [9].
Quercetin is one of the phytochemicals that is widely
found in foods consumed daily. This polyphenol com-
pound widely exists in nuts, teas, vegetables, herbs and
generally daily diet of people [10]. Also, it is available as
commercial supplement. It is safe at oral dosages of 1 g/
day which is absorbed up to 60% [11]. Quercetin has an
extended variety of pharmacological usages such as anti-
oxidant, anti-diabetic, anti-inflammatory and anti-
proliferative functions [12–14]. Quercetin, 2-(3,4-dihy-
droxyphenyl)-3,5,7-trihydroxy4H-chromen-4-one, is well
known by its 2-hydroxyflavone backbone consisted of
two benzene rings, A and B, linked by a 3-carbone het-
erocyclic pyrone one [13]. The strong ability of quercetin
in free radical scavenging and binding to transition metal
ions is due to the presence of two antioxidant pharma-
cophores in its structure [13]. In addition, the presence
of catechol and the OH group at position C3 of its struc-
ture provide a great configuration for scavenging of free
radicals [13, 15]. Quercetin is a pentalhydroxyflavonol
which has 5 hydroxyl groups on its flavonol skeleton at
3, 30, 40 5, and 7 position carbons. Various biochemical
and pharmacological functions of quercetin result from
the substitution of its different functional groups [16].
Several investigations showed that quercetin could be
present in two ways: free state or aglycone and conju-
gated by various molecules such as carbohydrates, lipids,
alcohols, and sulfate group which produce quercetin de-
rivatives, including quercetin glycoside, prenylated quer-
cetin, quercetin ethers and quercetin sulfate [16].
Moreover, a large amount of research on this bioactive
compound has proposed several pathways which interact
to treat cancer [17, 18]. Several evidences revealed the
inhibitory effects of quercetin against wide variety types
of cancers, including breast, lung, nasopharyngeal, kid-
ney, colorectal, prostate, pancreatic, and ovarian cancer
[19–22]. Previous studies have reported that consump-
tion of quercetin-high rich vegetables was related to a
decreased risk of ovarian cancer [23–25]. Likewise, con-
sumption of fruits contains quercetin such as apples and
citrus fruit juices reduce the incidence of ovarian cancer
[26]. Several studies have investigated cytotoxic effects
of quercetin on ovarian cancer cells both in vitro and in
vivo. While quercetin do not harm healthy cells, it has
been identified to be cytotoxic to cancer cells via various
mechanisms suggesting to be an ideal agent for ovarian
cancer treatment or an adjuvant agent in combination
with other anti-cancer drugs [27]. Thus, in this review,
we focused on chemo-preventive and curative attitude of
quercetin for ovarian cancer and summarize some of the
most recent findings which regard the possible molecu-
lar mechanisms by which this natural compound inhibits
this cancer.
Ovarian cancer carcinogenesis and progression: molecular
mechanisms
There are several theories about the processes by which
ovarian cancer progresses. One of them is ovulation the-
ory suggests that frequent ovulation with recurrent
breakdown and repair of ovarian epithelium elevates the
possibility of DNA damage and carcinogenesis [28].
Therefore, more ovulations provide higher risk of ovar-
ian cancer development. Hyper-ovulation in rats signifi-
cantly elevates the possibility of ovarian adenocarcinoma
progression. Some experimental studies revealed that
ovulation may lead to carsinogenesis by initiating
multiple cellular events [29]. Hence, excessive ovulation
increases the risk of mutagenicity which may be inter-
vened by inflammation. Various inflammatory mediators
such as prostaglandins and leukoteriens as well as vaso-
active substances such as bradykinin are increased dur-
ing ovulation. Follicle rupture which occurs during
ovulation has also features of inflammation. Taken to-
gether, the process of ovulation is strongly associated
with inflammatory reactions. Especially, epithelium lo-
cated around the ovulation site, have more contacts with
inflammatory mediators such as cytokines, prostaglan-
dins and oxidative stress [30]. Another theory is gonado-
trophin theory which suggests that increased levels of
gonadotrophins induce epithelium proliferation within
inclusion cysts directly or by the stimulation of steroido-
genesis leading to neoplastic transformation [31]. Data
also reported that reproductive hormones are related to
ovarian cancer carcinogenesis as progestins which have
pro-apoptotic actions, reduce the risk of tumor trans-
formation while estrogen promotes malignancy [32].
Moreover, chronic inflammation has also been suggested
to play potential role in ovarian cancer development
[33]. Epithelial ovarian cancer cells are able to
metastasize to the peritoneal cavity and lead to an accu-
mulated ascites which provide an immunosuppressive
microenvironment exacerbating tumor development.
Ascetic fluid activates protein kinase B (or Akt) and
prevents apoptosis induced by tumor necrosis factor
receptor apoptosis-inducing ligand (TRAIL) [34]. The
dynamic alteration in cytokines of ascites has been
indicated in a recent study in which ascites and plasma
samples of advanced epithelial ovarian cancer showed a
remarkable change in cytokines and inflammatory mole-
cules [35]. Moreover, a wide variety of inflammatory
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agents, including interleukin-6 (IL-6), Akt, lysophospha-
tidyl acid (LPA) and protein kinase C (PKC) have been
found to be elevated in ovarian cancer [36]. LPA is iden-
tified to elevate IL-6, IL-8 and VEGF through Akt/ nu-
clear factor kappa B (NF-kB) pathway in ovarian cancer
cells [37]. PKC also plays a vital modulatory role in a
large number of signal transduction pathways of cancer.
Impairment in PKC function has been observed in
tumorogenesis and drug-resistance related to ovarian
cancer [38]. Altogether, these mentioned agents and
pathways actively enhance ovarian cancer related to in-
flammation. Inflammation naturally generates several
toxic oxidant agents which causes directly damage of
DNA, proteins, and lipids leading to carcinogenesis [39].
Additionally, chronic inflammation is related to elevated
cell proliferation. Excessive and rapid cell division causes
additional replication errors resulting in DNA repair and
thereby may elevate mutagenesis risk [40]. Ovarian can-
cer cells release several inflammatory mediators, cyto-
kines and interleukins [41]. For example, prostaglandins
levels are greater in ovarian tumors than normal cells
[42]. Elevated levels of prostaglandins stimulate the inva-
sion of cancer cells [43]. Another important event which
is developed during ovarian cancer is oxidative stress.
Findings have reported that patients with ovarian cancer
have reduced concentrations of antioxidants and greater
levels of oxidative stress than healthy women [44–47]. In
previous studies, it has been observed that epithelial tis-
sues of ovarian cancer exert a pro-oxidant condition
with elevated expression of pro-oxidant enzymes and re-
duced expression of antioxidant enzymes. Elevated ex-
pression of inducible nitric oxide synthase (iNOS),
myeloperoxidase (MPO), NAD(P) H oxidase, and nitric
oxide (NO) as well as lowered apoptosis have been ob-
served in ovarian cancer tissues [45, 48, 49]. Moreover,
increased nitrosylation of caspase-3 which leads to a sig-
nificant reduction in the activity of caspase-3 was seen
in ovarian tumors. MPO is an important oxidant enzyme
which enhances the production of NO from iNOS [50,
51]. Many recent data reported an elevation in MPO
levels of ovarian cancer cells [52]. MPO also has key
roles in the regulation of apoptosis, immune surveillance
mechanisms, 3-nitrotyrosine formation, and inflamma-
tory responses [45]. Additionally, MPO as a source of
free iron promotes oxidative stress through contributing
to reactive oxygen species (ROS) generation. Under oxi-
dative stress, iron reacts with hydrogen peroxide (H2O2)
and thereby increases ROS production [47]. Above all,
oxidative stress may play a key role in ovarian cancer
maintenance and progression.
Anti-cancer effects of quercetin
Quercetin is a lipophilic compound which is able to cross
the cellular membranes and initiate multiple intracellular
signaling pathways implicated in chemoprevention. Sev-
eral investigations have reported the potential anti-cancer
effects of quercetin in wide variety types of cancers. One
of the unique abilities of quercetin is its dual function as a
pro-oxidant or antioxidant [53]. A ROS elevation result
from oxidative stress leads to DNA damage which is pro-
motes mutations. Mutations lead to uncontrolled growth
of malignant tumor cells. Quercetin can reduce ROS by
donating electrons and thereby decreased ROS-mediated
DNA damage [10, 54]. This is the primary antioxidant
mechanism of quercetin observed at its cellular concen-
trations which could be obtained by diet [55]. In contrast,
quercetin increases oxidative stress and cytotoxicity at
higher concentrations by elevating damage and inducing
apoptotic pathways in tumor cells [10, 54]. Quercetin is
also known as a great apoptosis inducer at its high con-
centrations. It is proved that mitochondrial-mediated
pathway is the main mechanism which quercetin used for
its apoptosis induction effect [56–58]. Quercetin induces
apoptosis through activation of p53, elevation of pro-
apoptotic molecules such as Bax, caspase-3, caspase-9 and
reduction of anti-apoptotic agents such as survivin and
Bcl-2 [59]. Several experimental studies revealed that
higher dosages of quercetin are also able to induce apop-
tosis via death-domain pathways in various cancer cells
[60]. In addition, emerging data is showing that quercetin
directly inhibits protein chaperons and thereby stimulates
apoptosis [61, 62]. Protein chaperons have role in protein
folding and maintenance that disruption in their perform-
ance leads to cell death. Un-regulation of heat shock pro-
tein (HSP) chaperones is induced by ionizing radiation in
many tumor cells. Recent findings revealed that quercetin
inactivates protein chaperons by inhibiting the kinases
which contribute to HSP induction [62]. Thus, quercetin
may be applied as an adjuvant in combination with
current chemotherapies in cancer treatment. Quercetin is
also observed to arrest cell cycle in several types of can-
cers. Quercetin down-regulates cyclin D1/Cdk4 and E/
Cdk2 and up-regulates p21 and thereby induces the G1
cell cycle arrest [63]. Similarly, in vitro studies have re-
ported that quercetin induces cell cycle arrest in G2/M,
G0/G1 and G2/M phases [20, 21]. Moreover, quercetin ar-
rests cell cycle in the S phase by inhibiting DNA synthesis
[64]. Quercetin-induced up-regulation of p21, p27, p53
and Chk2 along with down-regulation of Cdk1 and cyclin
B1 leading to cell cycle arrest in the G1 and G2/m phase,
have been observed in various cancer cell lines [65, 66].
Quercetin is able to directly bind tubulin by which in-
duce depolymerization of cellular microtubules leading
to cell cycle arrest [67]. Thus, quercetin affects a wide
variety of molecules involved in the cell cycle process.
PI3K-Akt/PKB pathway which is involved in several pro-
cesses such as cell survival regulation, cell cycle and
growth progression, and also carcinogenesis [68], can be
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targeted by quercetin in various types of cancers result-
ing in apoptosis induction and inhibition of cancer initi-
ation and development [69]. Furthermore, tyrosine
kinases are a kind of cancer-related molecules which
play role in the transduction of growth factors and onco-
genes. Recent findings revealed that quercetin inhibits
tyrosine kinases leading to inhibition of the growth of
tumor cells [70, 71]. Besides, p53 is a key molecule in
the anti-cancer and pro-apoptotic effects of quercetin.
Several studies have reported that quercetin induced
phosphorylation and stabilizing of p53 levels. For in-
stance, in HepG2 cells quercetin contributed to p53 ex-
pression and phosphorylation leading to cell cycle arrest
and apoptosis induction [72]. Moreover, in colon carcin-
oma cells, quercetin and p53 contribution also resulted
in increased expression of NAG-1 and thereby increased
apoptosis [73]. Also, P53 increases p21 levels attenuating
the pro-apoptotic effects of quercetin in cancer cells. On
the other hand, p53 has antioxidant function by regulat-
ing of several genes, including microsomal GSH trans-
ferase homolog PIG12, Gpx1, aldehyde dehydrogenase
ALDH4A1, Mn-SOD2, and catalase [74–76]. In oxida-
tive stress condition, p53 is essential for decreasing
intracellular ROS concentrations. Additionally, de-
creased p53 sensitizes cells to damage of H2O2 which
leads to decreased viability, increased apoptosis and ele-
vated DNA oxidation. However, in cancer cells p53 func-
tions are significantly blocked by down-regulating of its
gene. So quercetin may improve ROS elevation induced
by p53 deficiency through elevating of its levels [77].
Taken together, these findings highlight the significant
effects of quercetin in cancer treatment. Apoptosis in-
duction, pro-oxidant and antioxidant actions, cell cycle
arrest induction, regulation of several cancers related
proteins such as p53, HSPs, and tyrosine kinases are
some mechanisms recently reported by which quercetin
can inhibit cancers.
Quercetin and ovarian cancer
Recently, the effects of quercetin on ovarian cancer have
been interesting for many researchers. In this way, sev-
eral experimental studies have been conducted to eluci-
date the mechanisms by which quercetin inhibits
ovarian cancer. Liu Y et al. [78] investigated the effect of
quercetin on apoptosis in mice with ovarian cancer. The
results showed that quercetin induced apoptosis via the
mitochondria intrinsic and caspase-dependent pathways.
Besides, quercetin evoked endoplasmic reticulum (ER)
stress in ovarian cancer resulting in mitochondria-
mediated apoptosis. Furthermore, quercetin was able to
induce autophagy which has a protective role in ovarian
cancer cells. Taken together, this study indicated that
quercetin induced ER stress, apoptosis and authophagy
via a p-STAT3/Bcl-2 axis. Another investigation reported
that quercetin decreases the viability and induces apop-
tosis of metastatic ovarian cancer cells. Quercetin de-
creases several anti-apoptotic molecules, including Bcl-2
and Bcl-xL and increases pro-apoptotic molecules, in-
cluding caspase-3, caspase-9, Bid, Bax, Bad and cyto-
chrome c. In addition, quercetin inhibits the growth of
metastatic ovarian cancer cells by the induction of
mitochondrial-mediated apoptosis [79]. In a recent
study, anti-cancer effects of nano-formulation of quer-
cetin were examined. This form of quercetin signifi-
cantly inhibited growth of ovarian cancer cells both in
vitro and in xenograft ovarian cancer mice. Furthermore,
nano-formulated quercetin induced apoptosis by activat-
ing caspase-3, caspase-9 and Bax as well as reducing
MCL-1 and Bcl-2 [80].
Several experiments have examined the synergistic ef-
fect of quercetin in combination with other chemothera-
peutic agents against ovarian cancer. Gong c et al. [81]
assessed the effect of quercetin in combination with ir-
radiation on ovarian cancer in an in vitro/in vivo study.
Quercetin treatment led to ER stress, increased expres-
sion of p53, p21 and Bax, decreased expression of Bcl-2,
prolonged DNA repair as well as induced radio-
sensitization in ovarian cancer cells. In human ovarian
cancer xenograft model, quercetin in combination with
radiation significantly inhibited tumor growth and acti-
vated p53. In another recent report, quercetin pretreat-
ment strongly potentiated cisplatin cytotoxicity in
ovarian cancer. Quercetin increased ER stress, inhibited
STAT3 phophphorylation, downregulated Bcl-2 expres-
sion in ovarian cancer cells. In xenograft mous model of
ovarian cancer, quercetin also increased anti-tumor ef-
fects of cisplatin. In mice treated with cisplatin in com-
bination with pretreatment of quercetin, lowered Bcl-2
and higher apoptosis were observed compared with
other groups. This study suggested that quercetin may
be a good candidate for adjuvant therapy in ovarian can-
cer treatment [82]. Another form of quercetin, PEGy-
lated liposomal quercetin (Lipo-quercetin) was evaluated
on cicplatin-sensitive and cisplatin-resistant human
ovarian cancer models both in vitro and in vivo. In vitro
investigations reported that Lipo-quercetin suppressed
cell growth and induced apoptosis and cell cycle arrest
in both tumor cell types. Experiments in ovarian cancer
xenograft models of mice showed that Lipo-quercetin
more inhibited tumor proliferation compared with free
quercetin. Moreover, Lipo-quercetin induced apoptosis
in in vivo study [83]. Likewise, another in vitro study
supported the synergistic effect of quercetin in combin-
ation with cisplatin in ovarian cancer cells [84]. Some
studies have investigated the influences of quercetin on
cell cycle progression. The cell cycle modulation and
cytotoxic effect of quercetin on ovarian cancer cells was
investigated in an in vitro study. Findings showed that
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quercetin decreased the expression of cycline D1 with-
out influence on cyclin B1 which could be associated
with G1/S phase alteration [85]. In an experimental
study, quercetin could inhibit proliferation and induce
apoptosis in ovarian cancer cells in a dose manner. The
protein levels of survivin were decreased when the quer-
cetin dose increased. Quercetin also led to cell cycle ar-
rest in G0/G1 phase and G2/M phase [86]. Another
study revealed that quercetin may arrest the cell cycle
via inhibiting 1-phosphatidylinositol 4-kinase (PI kinase)
Table 1 Experimental studies that investigated the role of quercetin in ovarian cancer
Form of quercetin Doses Type of cervical cancer Model Findings Ref
Quercerin 80 mg/kg twice a week – In vivo Induced apoptosis, induced ER stress,
activated p-STAT3/ Bcl2 axis, induced
protective authophagy,
[78]
34′7TMQ – Epithelial and fibroblast ovarian
cancer cell lines
In vitro Inhibited cell migration and invasion,
inhibited expression of uPA and
MMP-2
[90]
Quercetin A dose range Metastatic ovarian cancer cell line In vitro Decreased viability, induced apoptosis,
decreased Bcl-2 and Bcl-xL, increased
caspase-3, caspase-p, Bid, Bad, Bax,
cytochrome c
[79]
Quercetin 100 μM Multi-drug resistant ovarian cancer
cell line
In vitro Increased ER stress, prolonged DNA
repair, increased expression of p53,
p21 and Bax, decreased expression
of Bcl-2, induced radio-sensitization,
[81]
Quercetin – Human ovarian cancer xenograft
model
In vivo increased radiation-induced cell death,
increased p53, increased ER stress
Quercetin A dose range Cisplatin sensitive and resistant
cell lines
In vitro Enhanced cisplatin cytotoxicity, increased
ER stress, suppressed STAT-3
phosphorylation, decreased expression
of Bcl-2,
[82]
40 mg/kg once a week Human ovarian cancer xenograft
model
In vivo Suppressed STAY-3 phosphorylation,
decreased Bcl-2 expression, induced
apoptosis
Quercetin A dose range Epithelial ovarian cancer cell line
and its CIS-resistant cell line
In vitro Decreased expression of cyclin D1 [85]
Quercetin A dose range Epithelial ovarian cancer cell line In vitro Inhibited proliferation, induced
apoptosis, decreased survivin, induced
cell cycle arrest
[86]
Nano-formulation of quercetin A dose range Ovarian endometrioid
adenocarcinoma
In vitro Inhibited growth, induced apoptosis,
activated caspase-3 and caspase-9,
decreased expression of MCL-1 and
Bcl-2, increased expression of Bax
[80]
A dose range Human ovarian cancer xenograft
model
In vivo Inhibited growth, induced apoptosis,
inhibited angiogenesis
Quercetin A dose range Epithelial and drug resistant ovarian
cancer cell lines
In vitro Decreased ROS, increased anti-oxidant
enzymes, inhibited apoptosis
[91]
Human ovarian cancer xenograft
model
In vivo Increased anti-oxidant enzymes
expression, reduced ROS, decreased
anti-neoplastic drug’s efficacy
Lipo-Que – CIS-resistant and CIS-sensitive
ovarian cancer cell lines
In vitro Inhibited proliferation, induced
apoptosis, induced cell cycle arrest
[83]
Human ovarian cancer xenograft
model
In vivo Inhibited tumor growth, inhibited
proliferation, induced apoptosis
Quercetin 2 mg / kg Human ovarian cancer xenograft
model
In vivo Increased TRAIL sensitization, inhibited
tumor growth, increased caspase-3,
induced apoptosis
[88]
Quercetin 10 microM Ovarian serous adenocarcinoma In vitro Increased TGF beta 1 activity [89]
Quercetin A dose range Metastatic ovarian serous
adenocarcinoma
In vitro Inhibited PI kinase, decreased IP3 levels [87]
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activity and reducing inositol-1,4,5-triphosphate (IP3)
levels [87]. Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) has been proven to have an-
titumor activity in several cancer types including ovar-
ian cancer. Yi L et al. [88] evaluated the effect of
quercetin on sensitization of ovarian cancer cells to
TRAIL. Results indicated that quercetin elevated the
sensitization of tumor cells to TRAIL leading to re-
duced expression of cell survival proteins, inhibited
tumor growth and increased pro-apoptotic proteins
including caspase-3. Scambia et al. [89] demonstrated
that quercetin inhibited growth of ovarian cancer cells
via modulating transforming growth factor beta 1
(TGF-beta-1) production. Results indicate that quer-
cetin increased TGF-beta-1 activity. Northern blot
analysis revealed no alteration in TGF-beta-1 mRNA
levels suggesting that TGF-beta-1 modulation occurs
at posttranscriptional levels. In an in vitro study, the
effect of methylquercetin, 3,4′,7-O-trimethylquercetin
(34′7TMQ) on proliferation, invasion and migration
of ovarian cancer cells were measured. In mentioned
study, the expression of proliferating cell nuclear anti-
gen (PCNA) urokinase plasminogen activator (uPA),
plasminogen activator inhibitor-1(PAI-1) and MMP-2
were analyzed. The results indicated that 34′7TMQ
inhibited the migration and the invasion of ovarian
cancer cells but had no effect on cell proliferation.
After 34′7TMQ treatment, the expression of uPA and
MMP-2 also inhibited, but PAI-1 and PCNA levels
were not changed [90]. In contrast to above results
which revealed the beneficial effects of quercetin in
ovarian cancer treatment especially in combination
with other treatments, a recent experimental study re-
ported that quercetin lowered the effects of some anti-
neoplastic drugs including cisplatin, 5-fluorouracil,
taxol, and pirarubicin. Low concentrations of quer-
cetin had anti-apoptotic effect and decreased ROS-
mediated injury of anti-neoplastic drugs and also
increased antioxidant enzymes in tumor cells [91].
Taken together, these findings have demonstrated that
quercetin exerts antitumor features against ovarian
cancer via several mechanisms (Table 1).
Fig. 1 Schematic representation in targeting different signaling pathways using quercetin as a novel therapeutic strategy in the treatment of
ovarian cancer
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Conclusions
In etiology of ovarian cancer, several molecular mecha-
nisms, including inflammation, oxidative stress and DNA
damage are complicated. Findings reported that quercetin
inhibits ovarian cancer by its anti-inflammatory, pro-
oxidative, anti-proliferation, apoptosis induction, and cell
cycle arrest induction activities. Besides, this natural
compound can intensify the effects of other chemo-
therapeutic drugs (Table 1 and Fig. 1). However, more in-
vestigations are required to completely elucidate its exact
mechanisms of action against ovarian cancer. Collectively,
quercetin may be a good candidate for ovarian cancer
treatment especially in combination with other chemo-
preventive drugs due to its potential synergistic effects.
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